Biotest AG: Biotest increases sales and earnings
Biotest AG / Quarter Results
05.11.2009
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Biotest increases sales and earnings
- Nine-month figures: sales increase by 12.0%, while EBIT grows by 3.0%
- Forecast for the full year 2009 confirmed
Dreieich, 5 November 2009. In the first nine months of 2009, the Biotest
Group increased sales and earnings compared with the previous year's
figures in the same period. Sales increased by 12.0% to EUR361.9 million
(2008: EUR323.0 million). The main reason for this was the continuing
success in its Plasma Proteins business, where Biotest increased sales by
12.8%. Biotest also achieved substantial sales increases in its other
segments, Medical Diagnostics and Microbiological Monitoring.
After nine months, the Group's earnings before interest and tax (EBIT) were
3.0% up, at EUR45.2 million, year-on-year (EUR43.9 million). Earnings per
share grew by 10.7% to EUR1.97 (EUR1.78).
Biotest has achieved further important milestones in its research and
development projects. Further analysis of a Phase II trial produced new
data on the efficacy of the monoclonal antibody BT-061, which Biotest is
developing for the indications rheumatoid arthritis and psoriasis. In
September 2009, a Phase I trial of BT-063 in the indication systemic lupus
erythematosus (SLE) started. This means that all three monoclonal
antibodies in the Biotest pipeline are now undergoing clinical trials.
The Board of Management confirmed the target set out in the 2008 Annual
Report, namely to achieve a 10% year-on-year increase in the Biotest
Group's sales in 2009. As far as EBIT is concerned, Biotest's objective is
still to match the very good result achieved in 2008.
The current quarterly report as well as the charts for the analyst
conference contain detailed information on business development in the
segments and progress in implementing corporate strategy. The report and
the charts can be downloaded from the company's website (www.biotest.de).
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs as well as
reagents and systems for diagnostics and microbiology. With a value added
chain that extends from pre-clinical and clinical development to worldwide
sales, Biotest has specialised primarily in the areas of application of
immunology and haematology. In its Plasma Protein segment, Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In the Biotherapeutic segment, Biotest researches
into the clinical development of monoclonal antibodies, including in the
indications of rheumatoid arthritis and cancer of plasma cells. The
products of the Microbiological Monitoring segment are primarily used in
hygiene monitoring, while those of Medical Diagnostics are used, for
example, in blood transfusions and transplants. Biotest has more than 2,000
employees worldwide. The preference shares of Biotest AG are listed in the
SDAX on the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard/Official traded
Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart
05.11.2009 Financial News transmitted by DGAP
---------------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Deutschland
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations@biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------------
